Evidence map›Paper›PMID 33794845›Full record

Observational studyBMC pulmonary medicine2021

Correlation between loss of Smad4 and clinical parameters of non-small cell lung cancer: an observational cohort study.

Xiangjun Guo, Mengmeng Li, Xin Wang, Yun Pan, Jiashu Li

Open access · goldAbstract readObservational Study
In one paragraph

Observational study in BMC pulmonary medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
0.2field-weighted citation impact, top 48% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 5 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Xiangjun GuoDepartment of Respiratory and Critical Care Medicine, The First People's Hospital of Lianyungang City, Lianyungang, Jiangsu, China.
Mengmeng LiDepartment of Respiratory and Critical Care Medicine, The First People's Hospital of Lianyungang City, Lianyungang, Jiangsu, China.
Xin WangDepartment of Respiratory and Critical Care Medicine, The First People's Hospital of Lianyungang City, Lianyungang, Jiangsu, China.
Yun PanDepartment of Respiratory and Critical Care Medicine, The First People's Hospital of Lianyungang City, Lianyungang, Jiangsu, China.
Jiashu LiDepartment of Respiratory and Critical Care Medicine, The First People's Hospital of Lianyungang City, Lianyungang, Jiangsu, China. ljslygrmyy@163.com.
The First People’s Hospital of Lianyungang · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundSMAD4 has been found to be inactivated to varying degrees in many types of cancer; the purpose of this study was to investigate the correlation between SMAD4 expression in non-small cell lung cancer (NSCLC) and clinical pathological parameters.

methodsThe serum concentration of SMAD4 was measured by enzyme-linked immunosorbent assay and its histological expression was quantified by immunohistochemistry.

resultsThe serum concentration of Smad4 in patients with NSCLC was lower than that in benign lung disease patients and healthy individuals (P < 0.001) and its concentration was related to the histological classification, pathological differentiation, lymphatic metastasis and clinical stage of NSCLC. The sensitivity and specificity of serum Smad4 were 91.56% and 61.56% for screening NSCLC from healthy individuals and 84.55% and 60.36% for screening NSCLC from patients with benign lung disease. Logistic regression analysis showed that the degree of cell differentiation (P < 0.001), lymph node metastasis (P < 0.001) and clinical stage of NSCLC (P = 0.007) affected the expression of Smad4, and had a strong correlation with the expression of Smad4. The expression of Smad4 in NSCLC tissues was lower than that in normal lung tissues (P = 0.009) and its expression was related to the degree of tissue differentiation, lymph node metastasis and clinical stage (P < 0.05).

conclusionsThe downregulation or deletion of Smad4 is related to the malignant biological behavior of NSCLC and serum Smad4 could be considered as a potential molecular indicator for diagnosis and evaluation of NSCLC.

Indexed as

AdultAgedBiomarkers, TumorCarcinoma, Non-Small-Cell LungCase-Control StudiesFemaleHumansImmunohistochemistryLogistic ModelsLungLung NeoplasmsLymphatic MetastasisMaleMiddle AgedNeoplasm StagingROC CurveBiomarkers, TumorSmad4 ProteinSMAD4 protein, humanDiagnosisEvaluationNon-small cell lung cancerNSCLCSmad4

Identifiers

PMID33794845
PMCPMC8017835
OpenAlexW3140339817

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.